MAPT and Alzheimer disease: Our secondary aim was to examine how proteomic changes in the mouse ChP were mirrored in the CSF and to compare this to human CSF proteomics findings in AD participants with amyloid but without tau pathology (A+T−) or with amyloid and tau pathology (A+T+) across the clinical spectrum.